Overview
Practical Considerations for Patients with PAD Post-Revascularization
The Expert Circle
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This vlog provides learners with the perspective of a leading vascular medicine expert, Dr. Anahita Dua, on recent advances and practical considerations for patients with PAD post-revascularization. Talking points include the latest approvals and evidence, real-world implications of these recent advances, and roles of the interdisciplinary team in the management of this patient population.
This activity is intended for cardiologists, hospitalists, primary care clinicians, vascular surgeons, and other clinicians in the interdisciplinary PAD team.
The purpose of this activity is to provide learners with a brief and engaging activity to provide current guidance and limitations with recommendations for patients with PAD post-revascularization, as well as understand the implications of recent evidence. Learners post-activity will be better able to tailor personalized treatment regimens for patients with PAD post-revascularization with respect to the latest clinical trial data and expert insights, and understand the role of the interdisciplinary team with post-revascularization care.
Upon completion of this activity, participants will be able to:
• Identify current antiplatelet and anticoagulant practices for patients with PAD post-revascularization
• Outline practical implications of recent advances for patients with peripheral artery disease (PAD) post-revascularization
• Create effective treatment plans for patients with PAD post-revascularization secondary to the latest research and expert insights
• Identify current antiplatelet and anticoagulant practices for patients with PAD post-revascularization
• Outline practical implications of recent advances for patients with peripheral artery disease (PAD) post-revascularization
• Create effective treatment plans for patients with PAD post-revascularization secondary to the latest research and expert insights
This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.
This activity was part of a serial learning curriculum. This functionality is no longer available due to activity expiration.
Anahita Dua, MBChB, MBA, MSc
Vascular Surgeon
Director MGH Vascular Lab
Co-Director of the MGH Vascular Lab
Associate Director of the MGH Wound Care Center
Massachusetts General Hospital
Boston, MA
Vascular Surgeon
Director MGH Vascular Lab
Co-Director of the MGH Vascular Lab
Associate Director of the MGH Wound Care Center
Massachusetts General Hospital
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Anahita Dua, MBChB, MBA, MSc
Speaker (Education): MiMedx Group, Inc. and Penumbra, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Aspirin for PAD, dual antiplatelet therapy (DAPT) for symptomatic PAD with recent coronary stent or acute coronary syndrome, DAPT for PAD post-endovascular revascularization
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
